You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 11,160,751

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,160,751 protect, and when does it expire?

Patent 11,160,751 protects XYOSTED (AUTOINJECTOR) and is included in one NDA.

This patent has seven patent family members in five countries.

Summary for Patent: 11,160,751

Title:	Hematocrit modulation through needle assisted jet injection of testosterone
Abstract:	The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
Inventor(s):	Wotton; Paul K. (Newtown, PA), Jaffe; Jonathan (Annandale, NJ)
Assignee:	ANTARES PHARMA, INC. (Ewing, NJ)
Application Number:	15/027,387
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 11,160,751

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-001	Sep 28, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY	⤷ Sign Up
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-002	Sep 28, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY	⤷ Sign Up
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-003	Sep 28, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 11,160,751

PCT Information
PCT Filed	October 07, 2014	PCT Application Number:	PCT/US2014/059443
PCT Publication Date:	April 16, 2015	PCT Publication Number:	WO2015/054213

International Family Members for US Patent 11,160,751

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2926439	⤷ Sign Up
European Patent Office	3054957	⤷ Sign Up
European Patent Office	3653213	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.